Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3856Neoplasms 2988Prostatic Neoplasms 1751Colorectal Neoplasms 1426Lung Neoplasms 1327Motor Activity 802Head and Neck Neoplasms 683Pancreatic Neoplasms 662Colonic Neoplasms 655Uterine Cervical Neoplasms 648Carcinoma, Non-Small-Cell Lung 629Carcinoma, Hepatocellular 628Rectal Neoplasms 569Stomach Neoplasms 544Brain Neoplasms 483Ovarian Neoplasms 438Anxiety Disorders 419Pain 418Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 374Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 339Melanoma 322Multiple Myeloma 320Lymphoma 305Depression 305Endometrial Neoplasms 289Liver Neoplasms 279

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Interventional × Hormone Refractory Prostate Cancer × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡